News & Updates Webinar

Webinar: Beyond X-ing the X-Waiver (3/9/2023)

February 15, 2023

At the end of 2022, President Biden signed into law the removal of the X-Waiver requirement to prescribe buprenorphine to treat opioid use disorder (OUD). This is seen as a first step towards increasing access to OUD treatment, however, X-ing the X-Waiver, on its own, may not drive the increases in buprenorphine prescribing where its needed most. Many primary care providers have not received training in OUD treatment and how to engage patients in long-term treatment or connect them to supports needed for recovery. New providers in all healthcare settings will need training, mentorship, and coaching, and FORE Board member Dr. Westley Clark has highlighted the need for continued efforts to reduce stigma, manage privacy, address disparities, and build a community of practice in which it is expected to care for OUD patients.

FORE leadership has highlighted some of the additional challenges ahead and many of our grantees are showing how these challenges can be met. One grantee is leading a national campaign to encourage other emergency department clinicians to treat OUD patients by leveraging social media and behavioral science to encourage clinicians to get the training they need to start to prescribe buprenorphine. Another is offering OUD treatment education to resident physicians, medical students, and physician assistant students. These are just a few examples of what next steps are needed to truly expand access to OUD treatment for all.

Please join us on Thursday, March 9th at 3pm EST as we welcome…

  • H. Westley Clark, MD, JD, MPH, Board Member
    Board of Directors
    Foundation for Opioid Response Efforts (FORE)
  • Alister Martin, MD, MPP, ER Physician & Assistant Professor
    Grantee: Massachusetts General Hospital
    Project: ‘Get Waivered’ National
  • Lara Weinstein, MD, MPH, DrPH, Associate Professor
    Grantee: Thomas Jefferson University
    Project: Lowering Barriers, Saving Lives, Reclaiming Health: Integrating Medications for Opioid Use Disorder

… as they discuss policy implications and next steps after removal of the X-Waiver and provide some recommendations for the field. The webinar will run until 4:30pm to allow for an extended discussion and Q&A session following the presentation.

Register for the Webinar Here

We invite you to look at our Resources page for the most up-to-date information and guidance. You can view a recording of our previous webinars below. As always, please reach out with questions and/or resources that you believe would benefits others.